Jagsonpal Pharmaceuticals Limited EBITDA for the year ending March 31, 2025: USD 5.98 M

Jagsonpal Pharmaceuticals Limited EBITDA is USD 5.98 M for the year ending March 31, 2025, a 54.11% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Jagsonpal Pharmaceuticals Limited EBITDA for the year ending March 31, 2024 was USD 3.88 M, a -12.43% change year over year.
  • Jagsonpal Pharmaceuticals Limited EBITDA for the year ending March 31, 2023 was USD 4.43 M, a 18.17% change year over year.
  • Jagsonpal Pharmaceuticals Limited EBITDA for the year ending March 31, 2022 was USD 3.75 M, a 16.90% change year over year.
  • Jagsonpal Pharmaceuticals Limited EBITDA for the year ending March 31, 2021 was USD 3.21 M, a 118.44% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)